BR112022018721A2 - Métodos de administração de uma preparação injetável de aripiprazol - Google Patents

Métodos de administração de uma preparação injetável de aripiprazol

Info

Publication number
BR112022018721A2
BR112022018721A2 BR112022018721A BR112022018721A BR112022018721A2 BR 112022018721 A2 BR112022018721 A2 BR 112022018721A2 BR 112022018721 A BR112022018721 A BR 112022018721A BR 112022018721 A BR112022018721 A BR 112022018721A BR 112022018721 A2 BR112022018721 A2 BR 112022018721A2
Authority
BR
Brazil
Prior art keywords
injectable preparation
aripiprazole
methods
administration
patient
Prior art date
Application number
BR112022018721A
Other languages
English (en)
Portuguese (pt)
Inventor
Harlin Matthew
Wang Xiaofeng
Wang Yanlin
Raoufinia Arash
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75581573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112022018721(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112022018721A2 publication Critical patent/BR112022018721A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
BR112022018721A 2020-04-01 2021-04-01 Métodos de administração de uma preparação injetável de aripiprazol BR112022018721A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
PCT/JP2021/014192 WO2021201238A1 (en) 2020-04-01 2021-04-01 Methods of administering an aripiprazole injectable preparation

Publications (1)

Publication Number Publication Date
BR112022018721A2 true BR112022018721A2 (pt) 2022-11-01

Family

ID=75581573

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022018721A BR112022018721A2 (pt) 2020-04-01 2021-04-01 Métodos de administração de uma preparação injetável de aripiprazol
BR112022018647A BR112022018647A2 (pt) 2020-04-01 2021-04-01 Métodos para dose de iniciação de tratamentos com aripipazol

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022018647A BR112022018647A2 (pt) 2020-04-01 2021-04-01 Métodos para dose de iniciação de tratamentos com aripipazol

Country Status (16)

Country Link
US (6) US20230129919A1 (cg-RX-API-DMAC7.html)
EP (3) EP3941470A1 (cg-RX-API-DMAC7.html)
JP (4) JP7584535B2 (cg-RX-API-DMAC7.html)
KR (3) KR20240165486A (cg-RX-API-DMAC7.html)
CN (3) CN115397420A (cg-RX-API-DMAC7.html)
AU (2) AU2021248212A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022018721A2 (cg-RX-API-DMAC7.html)
CA (3) CA3163321C (cg-RX-API-DMAC7.html)
ES (1) ES2995466T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20241574T1 (cg-RX-API-DMAC7.html)
HU (1) HUE069157T2 (cg-RX-API-DMAC7.html)
MX (2) MX2022012354A (cg-RX-API-DMAC7.html)
PL (1) PL4125903T3 (cg-RX-API-DMAC7.html)
TW (4) TWI865760B (cg-RX-API-DMAC7.html)
WO (2) WO2021201238A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202210633B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US20230129919A1 (en) 2020-04-01 2023-04-27 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments
WO2024194955A1 (en) 2023-03-17 2024-09-26 Otsuka Pharmaceutical Co., Ltd. Methods of dispersing aripiprazole injectable preparations
CN120957722A (zh) 2023-04-26 2025-11-14 大塚制药株式会社 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
BRPI0415531B8 (pt) * 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
KR101892745B1 (ko) 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
CA2655335C (en) 2007-12-19 2016-09-06 Janssen Pharmaceutica N.V. Prolonged-release injectable suspensions of paliperidone palmitate, and dosage forms and delivery systems incorporating same
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
KR20200010320A (ko) 2017-05-16 2020-01-30 보우 리버 엘엘씨 치료 방법
AU2019230014B2 (en) * 2018-03-05 2024-11-28 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
US20230129919A1 (en) 2020-04-01 2023-04-27 Otsuka Pharmaceutical Co., Ltd. Methods for dose initiation of aripiprazole treatments

Also Published As

Publication number Publication date
MX2022012353A (es) 2022-10-31
HUE069157T2 (hu) 2025-02-28
US20230129919A1 (en) 2023-04-27
KR20220161403A (ko) 2022-12-06
TWI906279B (zh) 2025-12-01
TW202200142A (zh) 2022-01-01
ZA202210633B (en) 2025-01-29
KR20240165486A (ko) 2024-11-22
AU2021248212A1 (en) 2022-12-01
CA3136727A1 (en) 2021-10-07
EP3941470A1 (en) 2022-01-26
MX2022012354A (es) 2022-10-31
EP4125903A1 (en) 2023-02-08
TWI865760B (zh) 2024-12-11
JP7584535B2 (ja) 2024-11-15
ES2995466T3 (en) 2025-02-10
US12691056B2 (en) 2026-07-28
WO2021201239A1 (en) 2021-10-07
CN119792290A (zh) 2025-04-11
US20240374506A1 (en) 2024-11-14
JP7891516B2 (ja) 2026-07-16
EP4125903B1 (en) 2024-10-09
JP2023520004A (ja) 2023-05-15
KR102732030B1 (ko) 2024-11-20
EP4467194A3 (en) 2025-01-08
AU2021245713A1 (en) 2022-12-01
PL4125903T3 (pl) 2025-02-03
JP2025176037A (ja) 2025-12-03
CA3163321A1 (en) 2021-10-07
JP7733000B2 (ja) 2025-09-02
US20220160621A1 (en) 2022-05-26
US20230225962A1 (en) 2023-07-20
TW202523329A (zh) 2025-06-16
EP4125903C0 (en) 2024-10-09
KR20220161402A (ko) 2022-12-06
TW202200141A (zh) 2022-01-01
WO2021201238A1 (en) 2021-10-07
BR112022018647A2 (pt) 2022-11-08
JP2023519425A (ja) 2023-05-10
CN115397420A (zh) 2022-11-25
US20260034053A1 (en) 2026-02-05
EP4467194A2 (en) 2024-11-27
CN115379842A (zh) 2022-11-22
CA3163321C (en) 2023-12-19
CA3212191A1 (en) 2021-10-07
HRP20241574T1 (hr) 2025-01-31
US20260115131A1 (en) 2026-04-30
JP2025020306A (ja) 2025-02-12
TW202615022A (zh) 2026-04-16

Similar Documents

Publication Publication Date Title
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
MX2022012354A (es) Metodos de administracion de una preparacion inyectable de aripiprazol.
BR112022001947A2 (pt) Combinações e composições de rna com propriedades imunoestimuladoras reduzidas
BR112022018236A2 (pt) Compostos antivirais e métodos para a sua administração
BR112018016341A2 (pt) solução de bloqueio do cateter e terapia de bloqueio do cateter
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
EP4487908A3 (en) Methods of treating crohn's disease and ulcerative colitis
BR112016000177A2 (pt) usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
Carlos et al. Orthognathic surgery with or without induced hypotension
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112018003232A2 (pt) terapias de combinação para tratamento de câncer
BR112021006548A2 (pt) sistema para tratamento personalizado imediato de um paciente em uma emergência médica
CO2018000196A2 (es) Agente terapéutico para tratar el síndrome de hunter y método de tratamiento
BR112023024741A2 (pt) Composto de quinolinamina, método de preparação para o mesmo e aplicação do mesmo em produtos farmacêuticos
BR112022007268A2 (pt) Dosagens e usos do fenilacetato de ornitina para o tratamento da hiperamonemia
BR112019018185A2 (pt) composição para tratar uma doença de articulação humana, e, kit.
BR112022018166A2 (pt) Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
BR112022018171A2 (pt) Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
BR112018016721A2 (pt) uso de di-hidrogeno fosfato de {6-[(e)-3-{metil[(3-metil-1-benfofuran-2-iol)metil]amino)-3-xopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)-il}metila e composição farmacêutica para tratamento de infecções bacterianas associadas ao pé diabético
Gao Wu et al. A costly lesson: Fatal respiratory depression induced by clindamycin during postoperative patient controlled analgesia
BR112017022478A2 (pt) composição farmacêutica de liberação sustentada que contém rivastigmina
BR112022006329A2 (pt) Método de tratamento de pacientes com síndrome hepatorrenal tipo 1 e pressão arterial média baixa
Usha et al. Accidental subcutaneous injection of vecuronium bromide in a patient with burns
Sharifnia et al. Effect of ephedrine on pain and hemodynamic status on injection of propofol